ArticleMovement disorders : official journal of the Movement Disorder Society2024
Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study.
Article in Movement disorders : official journal of the Movement Disorder Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of MRI-guided focused ultrasound lesioning for tremor-dominant Parkinson Disease: A systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- Magnetic resonance-guided focused ultrasound subthalamotomy for Parkinson's disease: a meta-analysis of effectiveness and safety.Neurosurgical review · 2026Pooled it
- Effectiveness and safety of magnetic resonance-guided unilateral focused ultrasound subthalamotomy for Parkinson's disease: a systematic review and meta-analysis of prospective studies.Frontiers in neuroscience · 2025Pooled it
- Deep Brain Stimulation after Subthalamic Focused Ultrasound for Parkinson's Disease.Movement disorders clinical practice · 2026Article
- The emerging role of high-intensity focused ultrasound (HIFU) as a symptomatic treatment for Parkinson's disease and essential tremor: a narrative review.Arquivos de neuro-psiquiatria · 2026Review
- Focused Ultrasound Ablation for Neurological Disorders.Biological psychiatry · 2026Review
- A narrative review of clinical and non-clinical determinants of health-related quality of life in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Surgical Treatment of Tremor Syndromes: A Guide to the Clinician.Movement disorders clinical practice · 2026Review
- Advanced Therapeutics in Parkinson's Disease: What's New?Current neurology and neuroscience reports · 2026Review
- High-intensity focused ultrasound (HIFU) versus deep brain stimulation (DBS) for refractory tremor: team HIFU.Arquivos de neuro-psiquiatria · 2025Review
- Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication-Refractory Parkinson's Disease Tremor.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Focused Ultrasound Lesioning of the Subthalamic Nucleus for Asymmetric Parkinson's Disease in Japan.Movement disorders clinical practice · 2025Article
- Bilateral Lesions in Parkinson's Disease: Gaps and Controversies.Movement disorders : official journal of the Movement Disorder Society · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnilateral subthalamic nucleus (STN) ablation using magnetic resonance-guided focused ultrasound (MRgFUS) is being explored as a new treatment for asymmetric Parkinson's disease (PD).
objectivesThe aims were to study the efficacy and safety of this treatment in asymmetric PD patients and to characterize the lesions.
methodsThis prospective, single-center, open-label study evaluated asymmetric PD patients at 6 (n = 20) and 12 months (n = 12) after MRgFUS lesion of the STN. The primary outcome was the change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS III), score in off medication on the treated side and the adverse events (AEs) at 6-month follow-up. We also evaluated cognitive-neuropsychological changes, self-assessment of clinical improvement, and the correlation of the lesion volume with the motor outcomes.
resultsOn the treated side, the MDS-UPDRS III score (mean difference = 13.8) and the scores in rigidity, bradykinesia, and tremor improved (P < 0.001) throughout the follow-up compared to baseline (at 6 months: rigidity mean difference = 2.8, improvement: 83.5%; bradykinesia mean difference = 6.0, improvement: 69.4%; tremor mean difference = 4.7, improvement: 91.5%). One patient had severe weakness in the treated hemibody, 1 had moderate dyskinesia, and 1 was in moderate confusional state that became mild (weakness) or completely resolved (dyskinesia and confusional state) at 6 months. The rest of the AEs were mild. We observed no clinically relevant changes in cognitive-neuropsychological tests. The percentage of ablation of the STN correlated with the improvement in the total MDS-UPDRS III and contralateral tremor scores (P < 0.05).
conclusionUnilateral MRgFUS lesion of the STN resulted in a significant motor improvement. We observed no persistent severe AEs, although mild, mostly transient AEs were frequent. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.